COMPANY OVERVIEW

Fractyl is focused on addressing insulin resistance to improve the health of people with some of the most common metabolic diseases, including type 2 diabetes and non-alcoholic steatohepatitis (NASH).

---

LOCATION

Lexington, MA, USA

---

THERAPEUTIC AREAS

Metabolic Disorders

---

WEBSITE

https://www.fractyl.com/

---

CAREER WEBSITE

https://www.fractyl.com/careers/

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Sep 28, 2023

Fractyl Health to Present Pioneering Data on Revita and Rejuva Programs at the European Association for the Study of Diabetes (EASD) 2023 Scientific Congress

Sep 14, 2023

Fractyl Health Welcomes Dr. Timothy Kieffer as Chief Scientific Officer

Aug 30, 2023

Fractyl Health Mourns the Passing of Esteemed Board Member Brian Dovey

Aug 1, 2023

Fractyl Health Announces Clinical Update on Revita Real World Registry in Germany and Launch of Revita+™ Telehealth Program Combining Behavioral Recommendations with Revita Treatment for Type 2 Diabetes

Jun 26, 2023

Fractyl Health Reports Durable Improvement in Glucose Control, Weight Loss, and Insulin Reduction in T2D Patients Using Revita in Open Label Phase of Revitalize 1 Pivotal Study at the American Diabetes Association 83rd Scientific Sessions

For More Press Releases

---